Barclays’s Kyverna Therapeutics KYTX Stock Holding History

Barclays’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Sell	136,375 -28,293	-17%	-$236K	﹤0.01%	2657
2025 Q4	$1.55M	Buy	164,668 +88,477	+116%	+$657K	﹤0.01%	3111
2025 Q3	$457K	Buy	76,191 +25,797	+51%	+$103K	﹤0.01%	3864
2025 Q2	$155K	Sell	50,394 -30,996	-38%	-$76.7K	﹤0.01%	4402
2025 Q1	$157K	Sell	81,390 -8,196	-9%	-$24.2K	﹤0.01%	4174
2024 Q4	$335K	Buy	89,586 +19,419	+28%	+$93K	﹤0.01%	4060
2024 Q3	$343K	Buy	70,167 +12,418	+22%	+$95.7K	﹤0.01%	4002
2024 Q2	$433K	Buy	57,749 +14,655	+34%	+$224K	﹤0.01%	3125
2024 Q1	$1.07M	Buy	+43,094	New	+$1.2M	﹤0.01%	3068

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Barclays's KYTX Position: Q1 2026 in Review

Barclays reduced its Kyverna Therapeutics (KYTX) stake by 17% in Q1 2026, selling an estimated $236K and leaving 136,375 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

Barclays first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.55M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Barclays held 136,375 shares of Kyverna Therapeutics worth $1.18M as of Q1 2026.
Barclays sold 28,293 Kyverna Therapeutics shares in Q1 2026, an estimated $236K.
Kyverna Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2657 holding.
Barclays first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
Barclays's Kyverna Therapeutics position peaked at $1.55M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.